Therapeutic | Orticumab |
Target | OxLDL |
Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSSISVGGHRTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARIRVGPSGGAFDYWGQGTLVTVSS |
Light Chain | QSVLTQPPSASGTPGQRVTISCSGSNTNIGKNYVSWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDASLNGWVFGGGTKLTVL |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Human Phage Display |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Abcentra, BioInvent International, Genentech |
Conditions Approved | na |
Conditions Active | Atherosclerosis, Psoriasis |
Conditions Discontinued | na |
Notes |